MXC , MGC PHARMA, LSE WYCKOFF accumulation phase DFollowing this analysis we are during PHASE D of the WYCKOFF accumulation schematic#2
( check it out on google or here in TradingView)
I'm waiting here for a breakout upwards to have the confirmation.
(You can find my related idea regarding (CBX , Cellular Good) where this analysis has been
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.3 GBP
−9.24 M GBP
469.82 K GBP
47.19 M
About ARGENT BIOPHARMA LIMITED
Sector
CEO
Roby Reuven Zomer
Headquarters
Subiaco
Website
Founded
2005
ISIN
AU0000326647
FIGI
BBG00Z3T1HW1
Argent BioPharma Ltd. engages in the production of medical marijuana. Its Endocannabinoid system covers all cells and nerves; it is the messenger of information flowing between immune system and the central nervous system. The company was founded by Roby Zomer on October 21, 2005 and is headquartered in Perth, Australia.
Mxc Lse falling wedge possible reversal . Mgc Pharmaceuticals listed in Lse is currently having a falling wedge started the 15th of September.
I've identified the yellow area around 2.44-2.56£ as possible entry for a long. Reversal pattern will be confirmed only above 2.96£ and the possible targets are 3.55 and 3.96.
Let me know in the
I like the stock!This type of company have the power to change this era. I'm in with 10k shares, plan to buy more for long-term (5-10 years).
See all ideas
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of RGT is 17.9 GBX — it has decreased by −2.94% in the past 24 hours. Watch ARGENT BIOPHARMA LIMITED ORD NPV (DI) stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange ARGENT BIOPHARMA LIMITED ORD NPV (DI) stocks are traded under the ticker RGT.
RGT stock has risen by 0.46% compared to the previous week, the month change is a −42.71% fall, over the last year ARGENT BIOPHARMA LIMITED ORD NPV (DI) has showed a −25.42% decrease.
RGT stock is 20.00% volatile and has beta coefficient of −1.99. Track ARGENT BIOPHARMA LIMITED ORD NPV (DI) stock price on the chart and check out the list of the most volatile stocks — is ARGENT BIOPHARMA LIMITED ORD NPV (DI) there?
Today ARGENT BIOPHARMA LIMITED ORD NPV (DI) has the market capitalization of 7.72 M, it has increased by 1.91% over the last week.
Yes, you can track ARGENT BIOPHARMA LIMITED ORD NPV (DI) financials in yearly and quarterly reports right on TradingView.
ARGENT BIOPHARMA LIMITED ORD NPV (DI) is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
RGT net income for the last half-year is −5.51 M GBP, while the previous report showed −3.78 M GBP of net income which accounts for −45.65% change. Track more ARGENT BIOPHARMA LIMITED ORD NPV (DI) financial stats to get the full picture.
No, RGT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ARGENT BIOPHARMA LIMITED ORD NPV (DI) EBITDA is −8.64 M GBP, and current EBITDA margin is −1.90 K%. See more stats in ARGENT BIOPHARMA LIMITED ORD NPV (DI) financial statements.
Like other stocks, RGT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ARGENT BIOPHARMA LIMITED ORD NPV (DI) stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ARGENT BIOPHARMA LIMITED ORD NPV (DI) technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ARGENT BIOPHARMA LIMITED ORD NPV (DI) stock shows the sell signal. See more of ARGENT BIOPHARMA LIMITED ORD NPV (DI) technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.